Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 24;10:12405. doi: 10.1038/s41598-020-69182-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Serum levels of TNFAIP3 in indicated longitudinal samples of MOG-AAD patients determined by ELISA: The graphs were made using GraphPadPrism version 8.4.2 (464) A TNFAIP3 levels in MOG-AAD patient#1 with 5 longitudinal samples, (1) Rm (remission, MOG-AAD#1.1), (2) Rm (remission, MOG-AAD#1.2), (3) PR (pre-relapse, MOG-AAD#1.3), (4) R (relapse, MOG-AAD#1.4), and (5) Rm/S (remission treated with steroid, MOG-AAD#1.5). B TNFAIP3 levels in MOG-AAD patient#5 with 8 longitudinal samples, (1) Rm (remission, MOG-AAD#5.1), (2) Rm (remission, MOG-AAD#5.2), (3) Rm (remission, MOG-AAD#5.3), (4) Rm (remission, MOG-AAD#5.4), (5) PR (pre-relapse, MOG-AAD#5.5), (6) Rm (remission, MOG-AAD#5.6), (7) Rm/Ct (mycophenolate mofetil treated at remission, MOG-AAD#5.7), and (8) Rm/Ct (mycophenolate mofetil treated at remission, MOG-AAD#5.8). C TNFAIP3 levels in MOG-AAD patient#6 with 3 longitudinal samples, (1) R/S (relapse treated with steroid, MOG-AAD#6.1), (2) Rm/Ct (mycophenolate mofetil treated at remission, MOG-AAD#6.2), and (3) Rm/Ct (mycophenolate mofetil treated at remission, MOG-AAD#6.3). D TNFAIP3 levels in MOG-AAD patient#7 with 2 longitudinal samples, (1) R/S (relapse treated with steroid, MOG-AAD#7.1), and (2) Rm/Rebif (remission treated with interferon beta-1a, MOG-AAD#7.2). E TNFAIP3 levels in MOG-AAD patient#8 with 2 longitudinal samples, (1) Rm (remission, MOG-AAD#8.1) and (2) R/S/Co (remission treated with steroid and Glatiramer acetate, MOG-AAD#8.2). F Mixed model paired analysis compared MOG-AAD patients, who had, both, relapse and remission samples. Relapse n = 8, Remission n = 22. The comparison between the relapse and remission group was done using Nonlinear Mixed-Effects Models library in R (nlme).